“Europe’s HIV Response at Crossroads: Tools Ready but 2025 Targets Remain Elusive Amid Persistent Barriers”

Europe is falling short of its 2025 HIV targets despite having effective tools, with persistent challenges including stigma, late diagnosis, and uneven access to care, particularly in Central and Eastern Europe. This report explores the situation based on recent expert analysis and data.

Europe’s 2025 HIV Target Overview

Europe, encompassing 53 countries across the WHO European Region, aimed for the ambitious 95-95-95 targets by 2025. These goals stipulate that 95% of people living with HIV (PLHIV) should know their status, 95% of those diagnosed should be on antiretroviral therapy (ART), and 95% of those treated should achieve viral suppression. Achieving these targets translates into at least 86% of all PLHIV having suppressed viral loads, which is crucial for reducing new HIV infections and related deaths.

While Western Europe is broadly on track for these goals, Central and Eastern Europe lag significantly. Overall viral suppression among those on treatment is strong across the region, but overall suppression for the entire population living with HIV remains too low due to gaps in diagnosis and treatment access.​

Key Challenges Undermining Progress

1. Late Diagnosis
   Awareness of HIV status remains uneven, with 94% in Western Europe knowing their status but only 88% in Central Europe and 80% in Eastern Europe. Late diagnosis exacerbates risks of transmission and poorer health outcomes.​

2. Access to Care and Treatment
   Treatment coverage similarly varies—Western Europe reports 96% of diagnosed PLHIV on treatment, Central Europe 94%, but Eastern Europe only 79%. This discrepancy is worsened by legal and systemic barriers faced by undocumented migrants and vulnerable populations, who often lack treatment access.​

3. Stigma in Healthcare and Society
   Stigma remains a major barrier in healthcare settings. One-third of PLHIV have not disclosed their status to family, and one in five to friends. Half avoid healthcare altogether due to fear of discrimination. Among healthcare workers, knowledge gaps about prevention methods like pre-exposure prophylaxis (PrEP) are common, and instances of unauthorized status disclosure occur.​

4. Uneven PrEP Implementation
   Pre-exposure prophylaxis (PrEP) is a powerful prevention tool shown to substantially reduce new HIV infections. The WHO goal is to have 500,000 people at high risk on PrEP by 2025. By late 2024, about 345,000 had accessed PrEP at least once, but 71% of users are clustered in a few Western European countries. Women and migrants are underrepresented among PrEP users, indicating access inequities.​

Epidemiological Trends and Targets

The overall incidence of new HIV infections in the European Region has risen by 5% compared with 2010, although the EU has achieved a 20% reduction. Deaths from HIV are decreasing in the EU but increasing in the broader European region, reflecting gaps in treatment access.​

Despite adding more than 540,000 people on ART since 2017 and delivering treatment to 71% of European PLHIV (below the global average of 77%), Europe remains behind global targets, especially outside Western Europe.​

Expert Insights and Recommendations

Teymur Noori, MSc, from the European Centre for Disease Prevention and Control, emphasizes the need to tackle stigma and ensure political and financial commitment to bridge these gaps. He highlights practical measures such as expanding routine opt-out HIV testing in emergency departments, scaling up PrEP, and guaranteeing treatment access to all populations, including undocumented migrants.​

Experts accord that the “95-95-95” cascade remains the most crucial framework, as improvements at each step amplify overall viral suppression, decreasing transmission risk. Achieving equity in HIV care across the socio-economic and geographic spectrum is key to closing the remaining gaps.​

Implications for Public Health and Individuals

For public health systems, closing the diagnosis and treatment gaps is critical to reversing the HIV epidemic trajectory. Ending stigma and discrimination, strengthening healthcare worker training, and ensuring inclusive policy frameworks can improve testing, treatment adherence, and prevention access.

For individuals, engaging in regular HIV testing, considering PrEP if at risk, and adhering to ART if diagnosed are vital practical steps. Access to updated information and supportive healthcare environments can empower people to better manage HIV risk and health outcomes.

Limitations and Contrasting Views

Data disparities persist due to heterogeneous healthcare infrastructure and reporting capacities across Europe. Some countries lack policies on providing care for undocumented migrants, while stigma and language barriers also complicate access for foreign-born populations. Although viral suppression among treated individuals is promising, substantial non-suppressed populations continue to fuel transmission.​

PrEP uptake lags in some regions, partly due to lack of awareness or regulatory barriers. The relatively low proportion of female and migrant PrEP users underscores gaps in reaching diverse at-risk groups.

Conclusion

Europe possesses effective tools to control HIV, including advanced ART, comprehensive testing strategies, and PrEP. Yet, achieving the 2025 milestones requires overcoming persistent barriers: stigma, uneven access, late diagnosis, and systemic inequalities. Success depends on inclusive policies, sustained investment, and addressing social determinants impacting HIV care and prevention.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References